Salvigenin
Based on 6 publication(s) in Google Scholar
Salvigenin is a natural polyphenolic compound, with neuroprotective effect. Salvigenin has antitumor cytotoxic and immunomodulatory properties. Salvigenin inhibits H2O2-induced cell apoptosis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.93%
- No. CAS: 19103-54-9
- Fòrmula: C18H16O6
- Peso molecular:328.32
-
Almacenamiento:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Medicine Food Homology Compound Library
HY-L055
-
Phenols Library
HY-L057
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Flavonoids Library
HY-L068
-
Neuroprotective Compound Library
HY-L070
-
Anti-Cancer Natural Product Library
HY-L107
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Membrane Protein-targeted Compound Library
HY-L149
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
PBCRBS Traditional Chinese Medicine Compound Library
HY-L193
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Posttranslational Modification Library
HY-L226
-
Mongolian Medicine Compound Library
HY-L238
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Salvigenin
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
IF
-
WB
-
Apoptosis Analysis
-
Histological Imaging/Staining
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MOLM-13 | IC50 |
2.6 μM
Compound: 31
|
Cytotoxicity against human MOLM-13 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human MOLM-13 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 33393294] |
| MV4-11 | IC50 |
2.6 μM
Compound: 31
|
Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 33393294] |
Salvigenin (0-100 μM, 3 h) protects SH-SY5Y cells against H2O2-induced cell death[1].
Salvigenin (0-100 μM, 2 h) significantly reduces ROS generation, increases the glutathione level, declines the extent of cell apoptosis and increases autophagy in H2O2-exposed SH-SY5Y cells[1].
Note: Please sterilize the working solution by using a 0.22 μm sterile filter membrane before cell experiments.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SY5Y cells exposed to H2O2 (300 μM)
-
Concentration:10, 25, 50, and 100 μM
-
Incubation Time:3 h
-
Result:Protected SH-SY5Y cells (best in 25 and 50μM) against H2O2-induced cell death.
-
Cell Line:SY5Y cells exposed to H2O2 (300 μM)
-
Concentration:10, 25, 50, and 100 μM
-
Incubation Time:2 h
-
Result:Significantly declined the extent of cell apoptosis induced by H2O2.
-
Cell Line:SY5Y cells exposed to H2O2 (300 μM)
-
Concentration:10, 25, 50, and 100 μM
-
Incubation Time:2 h
-
Result:Reduced cleaved caspase-3 and Bax/Bcl-2 ratio. Reduced caspase-12 and calpain levels. Reduced the level of Atg7, Atg12, and LC3-II/ LC3-I.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MCF-7 cell bearing inbred female Balb/c mice, aged from six to eight weeks[2]
-
Dosage:3.65, 5.85 and 9.68 μg/mouse/day for four days or 12 days
-
Administration:Intraperitoneal injection
-
Result:Showed a significant increase in DTH response in a dose-dependent manner. Significantly decreased the rate of tumor growth, increased lymphocyte proliferation index, increased the level of IFN-γ and decreased IL-4 production. Exhibited a significant decrease of the splenic CD4+CD25+Foxp3+ T lymphocytes.
Chemical Information
-
No. CAS 19103-54-9
-
Appearance Solid
-
Peso molecular 328.32
-
Fòrmula C18H16O6
-
Color White to yellow
-
SMILES
O=C1C=C(C2=CC=C(OC)C=C2)OC3=CC(OC)=C(OC)C(O)=C13
-
Synonyms
Psathyrotin
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Salvigenin mitigates neuronal ferroptosis by binding to PI3K and enhancing the interaction between VCP and PI3K in the repair of spinal cord injury. [Abstract]2025 Aug 19:147:157181. PMID: 40865346 -
Sci Rep
Investigation of Scutellaria Barbata's immunological mechanism against thyroid cancer using network pharmacology and experimental validation. [Abstract]2025 Jan 20;15(1):2490. PMID: 39833432 -
Biomedicines
Mechanistic Insights into Salvigenin for Glucocorticoid-Induced Femoral Head Osteonecrosis: A Network Pharmacology and Experimental Study. [Abstract]2025 Mar 3;13(3):614. PMID: 40149590
Salvigenin purchased from MedChemExpress. Usage Cited in: Biomedicines. 2025 Mar 3;13(3):614. [Abstract]
Cell viability assays using CCK-8 treated with Salvigenin (10, 20, 30, 40, 50 μM).
Salvigenin purchased from MedChemExpress. Usage Cited in: Biomedicines. 2025 Mar 3;13(3):614. [Abstract]
Immunofluorescence analysis of ESR1 expression (red) in MG63 cells under different treatments: control, Dex, and Dex+Salvigenin.
Salvigenin purchased from MedChemExpress. Usage Cited in: Biomedicines. 2025 Mar 3;13(3):614. [Abstract]
Representative protein bands for ESR1, Bax, Bcl-2, and Caspase-3, with GAPDH as the loading control treated with Salvigenin.
Salvigenin purchased from MedChemExpress. Usage Cited in: Biomedicines. 2025 Mar 3;13(3):614. [Abstract]
Representative dot plots showing early and late apoptotic cell populations under control, Dex, and Dex+Salvigenin treatments.
Salvigenin purchased from MedChemExpress. Usage Cited in: Biomedicines. 2025 Mar 3;13(3):614. [Abstract]
Hematoxylin and eosin (H&E) staining of femoral head sections showing trabecular bone structure and osteocyte distribution treated with Salvigenin.
-
J Nat Prod
Discovery and Characterization of Moracin C as an Anti-Gouty Arthritis/Hyperuricemia Candidate by Docking-Based Virtual Screening and Pharmacological Evaluation. [Abstract]2023 Sep 22;86(9):2091-2101. PMID: 37625387 -
J Mol Histol
Salvigenin: a natural ally against nasopharyngeal carcinoma's malignant phenotypes and immune evasion. [Abstract]2025 Oct 22;56(6):351. PMID: 41123682 -
Solvente y solubilidad
DMSO : 16.67 mg/mL (50.77 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2 mg/mL (6.09 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Rafatian G, et al. Increase of autophagy and attenuation of apoptosis by Salvigenin promote survival of SH-SY5Y cells following treatment with H₂O₂. Mol Cell Biochem. 2012 Dec;371(1-2):9-22. [Content Brief]
[2]. Noori S, et al. Antitumor and immunomodulatory effects of salvigenin on tumor bearing mice. Cell Immunol. 2013 Nov-Dec;286(1-2):16-21. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0458 mL | 15.2290 mL | 30.4581 mL | 76.1452 mL |
| 5 mM | 0.6092 mL | 3.0458 mL | 6.0916 mL | 15.2290 mL | |
| 10 mM | 0.3046 mL | 1.5229 mL | 3.0458 mL | 7.6145 mL | |
| 15 mM | 0.2031 mL | 1.0153 mL | 2.0305 mL | 5.0763 mL | |
| 20 mM | 0.1523 mL | 0.7615 mL | 1.5229 mL | 3.8073 mL | |
| 25 mM | 0.1218 mL | 0.6092 mL | 1.2183 mL | 3.0458 mL | |
| 30 mM | 0.1015 mL | 0.5076 mL | 1.0153 mL | 2.5382 mL | |
| 40 mM | 0.0761 mL | 0.3807 mL | 0.7615 mL | 1.9036 mL | |
| 50 mM | 0.0609 mL | 0.3046 mL | 0.6092 mL | 1.5229 mL |
Salvigenin Related Classifications
HY-N1318 Related Classifications
Powered by Bioz